Acesion Pharma Launches Phase 2 Trials for New AF Treatment AP31969 Acesion Pharma has initiated Phase 2 trials for AP31969, a promising treatment for atrial fibrillation, with a focus on safety and efficacy.

Acesion Pharma Launches Phase 2 Trials for New AF Treatment AP31969 #Denmark #Copenhagen #Atrial_Fibrillation #Acesion_Pharma #AP31969